Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Amarantus BioScience Holdings (AMBS) Starts Presentation at LD Micro Conference

Posted on December 2, 2014 by MissionIR

Amarantus BioScience Holdings is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The company has licensed Eltoprazine, a phase 2b ready small molecule indicated for Parkinson’s disease Levodopa induced dyskinesia and adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test for Alzheimer’s disease. For more information, visit the company’s website at www.amarantus.com

The three-day LD Micro Invitational in Bel Air, California, features company presentations from more than 200 select high-potential small-cap companies spanning multiple industries. Institutional and retail investors in attendance also have access to numerous networking opportunities and social events to learn more about these companies. For more information on LD Micro, visit www.ldmicro.com
This entry was posted in LD Micro Conference. Bookmark the permalink.

Comments are closed.